ProShares UltraPro Nasdaq Biotechnology (UBIO) Research
This fund aims to deliver daily returns equal to three times (3x) the daily movement of the NASDAQ Biotechnology Index, prior to accounting for fees and operating costs. To achieve this, it strategically deploys capital into various financial instruments, which ProShare Advisors expects will collectively mirror its ambitious daily performance target. The underlying index itself is a modified capitalization-weighted benchmark, comprising stocks of companies listed on Nasdaq that fall within the biotechnology or pharmaceutical sectors. It operates as a non-diversified fund.
Market snapshot
- Symbol
- UBIO
- Price
- $17.77
- Day change
- 0.00%
- Market cap
- $15.1M
- 52-week range
- 13.13-34.8
- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
Peer companies
- MicroSectors U.S. Big Banks Index 2X Leveraged ETNs (BNKO)
- Direxion Daily Cloud Computing Bear 2X Shares (CLDS)
- Merlyn.AI SectorSurfer Momentum ETF (DUDE)
- Credit Suisse FI Enhanced Europe 50 Exchange Traded Notes (ETNs) (FEUL)
- Direxion Flight to Safety Strategy ETF (FLYT)
- First Trust IndXX NextG ETG (FONE)
- Goldman Sachs Future Real Estate and Infrastructure Equity ETF (GREI)
- John Hancock Multifactor Financials ETF (JHMF)
Open ProShares UltraPro Nasdaq Biotechnology (UBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.